Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 2 (1)
P 3 (1)
P 4 (2)

Trial Status

Not Yet Recruiting2
Active Not Recruiting1
Unknown1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07682350Phase 2Not Yet Recruiting

SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

NCT07626645Not ApplicableNot Yet Recruiting

Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema

NCT07143773Phase 4Recruiting

SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients

NCT06933355Phase 4Active Not Recruiting

Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension

NCT01738074Phase 3Unknown

Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine

Showing all 5 trials

Research Network

Activity Timeline